(CercleFinance.com) – AstraZeneca’s Forxiga (dapagliflozin), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, has been approved in China to reduce the risk of sustained decreases in estimated glomerular filtration rate, renal failure terminal illness, cardiovascular death and hospitalization for heart failure in adults with chronic kidney disease at risk of progression with or without type 2 diabetes.
This condition affects 850 million people worldwide. However, diagnosis rates remain low and up to 90% of patients are unaware they have the disease.
The approval from China’s National Medical Products Administration is based on positive results from the phase III trial.
Sir Mene Pangalos, Executive Vice President, Bio-Pharmaceutical R&D, AstraZeneca said: ‘This approval marks an important milestone in our ambition to stop, reverse and ultimately cure chronic kidney disease worldwide.’
Forxiga (known as Farxiga in the United States) is now approved in 100 countries around the world, including the United States, European Union and Japan.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
